Home|Journals|Articles by Year|Audio Abstracts
 

Research Article

Open Vet J. 2024; 14(8): 2049-2056


Effect of Ginkgo biloba administration to apoptosis in rat (Rattus novergicus) brain cells exposed to Plumbum

Muhammad Hamdan, Widjiati Widjiati, Priya Nugraha, Jovian Philip Swatan.




Abstract

Background:
Lead (Plumbum/Pb) has been identified as a potential cause of Parkinson's disease as well as possibly contributing to disease progression. Ginkgo biloba extract has been widely used to prevent and treat stroke which prevents brain cell apoptosis and neuroinflammation. This has been shown to be beneficial in cognitive recovery in stroke incidents.
Aim:
This study aimed to determine the effect of Ginkgo biloba on the expression of Superoxide Dismutase (SOD), Malondialdehyde (MDA), and Apoptosis-Inducing Factor (AIF) in the brain cells of rats (Rattus novergicus) exposed to Plumbum.
Methods:
The experimental animals used were 36 male white rats divided into 4 groups with different treatments of Plumbum and Ginkgo biloba at varying doses for 42 days, after which the brains were collected for examination of SOD, MDA, and AIF expressions using immunohistochemical methods and analyzed using ANOVA and Duncan's test.
Results:
Plumbum administration caused a significant decrease in SOD expression and an increase in MDA and AIF expressions (p

Key words: Affordable Medicines, Brain cells, Ginkgo biloba, Plumbum






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.